Geraldine A Hamilton,
President/Chief Scientific Officer,
Emulate Inc
Dr. Hamilton's career spans academic research, large Pharma, and biotech start-ups, with over 10 years’ experience in the pharmaceutical industry. In all three arenas, Dr. Hamilton's work has focused on the development of new human-relevant cell-based models and their application to drug discovery. This pursuit brought Dr. Hamilton to Harvard's Wyss Institute, where as a Lead Senior Staff Scientist she directed the extensive Organs-on-Chips project. This project was successfully spun-out from the Wyss Institute to form Emulate, Inc., where Dr. Hamilton now serves as President and Chief Scientific Officer. At Emulate, Dr. Hamilton continues her work to further develop Organs-on-Chips technology as well as to drive and facilitate its adoption in commercial use. Prior to joining the Wyss Institute and Emulate, Dr. Hamilton was one of the founding scientists of the biotech start-up CellzDirect, where she was the VP of Scientific Operations and Director of Cell Products. CellzDirect successfully translated and commercialized technology from academic research to supply the pharmaceutical industry with hepatic cell products and services for safety assessment and drug-metabolism studies. Hamilton received her Ph.D. in cell biology/toxicology from the University of Hertfordshire (England) in conjunction with GlaxoSmithKline, followed by a post-doctoral research fellowship at the University of North Carolina. She has led in vitro toxicology and drug metabolism teams in GlaxoSmithKline and AstraZeneca. Her current research interests and scientific experience include: bioinspired engineering, toxicology and drug metabolism, liver cell biology, mechanisms regulating gene expression and differentiation, regulation of nuclear receptors and transcriptional activation in hepatocytes by xenobiotics, human cell isolation and cryopreservation techniques.
Organs-on-Chips: In vitro Surrogates for Accurate Human Bioemulation
All too often conventional cell-culture methods and animal testing fail
to serve as true predictive models, unable to recapitulate human organ
function or physiology. These shortcomings compel us to pursue more
"humanized" alternatives to the traditional approaches, as we strive to
attain authentic human response. This discussion will explore the
bioemulation capabilities of our Organs-on-Chips technology and its
potential use within drug development and safety pharmacology.
Organs-on-Chips are in vitro surrogates of the human body that may
accelerate the identification of novel therapeutics, ensure safety and
efficacy, and reduce significant drug development costs. We review our
platform and its incorporation of tissue-tissue interfaces, biochemical
cues, mechanical forces and physiological perfusion in an organ-specific
context. Our experience from organs such as the lung, liver, intestine
and kidney consistently shows that these bioengineered microenvironments
lead human cells to assume in vivo function and effectively reproduce
organ-level physiology and disease responses. Based on experimental data
collected from this platform, it is evident that Organs-on-Chips stand
as a more predictive, human-relevant alternative to traditional drug
development methods.
Organs-on-Chips: In vitro Surrogates for Accurate Human Bioemulation
All too often conventional cell-culture methods and animal testing fail to serve as true predictive models, unable to recapitulate human organ function or physiology. These shortcomings compel us to pursue more "humanized" alternatives to the traditional approaches, as we strive to attain authentic human response. This discussion will explore the bioemulation capabilities of our Organs-on-Chips technology and its potential use within drug development and safety pharmacology. Organs-on-Chips are in vitro surrogates of the human body that may accelerate the identification of novel therapeutics, ensure safety and efficacy, and reduce significant drug development costs. We review our platform and its incorporation of tissue-tissue interfaces, biochemical cues, mechanical forces and physiological perfusion in an organ-specific context. Our experience from organs such as the lung, liver, intestine and kidney consistently shows that these bioengineered microenvironments lead human cells to assume in vivo function and effectively reproduce organ-level physiology and disease responses. Based on experimental data collected from this platform, it is evident that Organs-on-Chips stand as a more predictive, human-relevant alternative to traditional drug development methods.
Add to Calendar ▼2015-07-08 00:00:002015-07-09 00:00:00Europe/LondonOrgan-on-a-Chip World Congress and 3D-PrintingOrgan-on-a-Chip World Congress and 3D-Printing in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com
